Objectives: To identify the most common pneumococcal serotypes in children hospitalized with invasive pneumonia, correlate isolated serotypes with those included in conjugate vaccines, and ascertain the sensitivity of the isolated pneumococcal strains to penicillin and other antibiotics.
Introduction
The estimated incidence of community-acquired pneumonia among children under five years of age in developing countries is approximately 151.8 million new cases per year, 11-20 million of which require hospitalization. 1 In developing countries, pneumonia occurs more often and is more severe than in developed nations, and carries higher incidence and mortality rates; pneumonia accounts for onefifth of under-five deaths in the developing world. 2 According to a 2008 article published in the Bulletin of the World Health Organization, 3 Brazil is among the top 15 countries in incidence of pneumonia -0.11 episodes per child-year among under-fives, which translates to 1.8 million cases per year. some European countries. 4 The frequency with which the various serotypes of S. pneumoniae occur and the extent of their role in causing invasive disease varies with time and place. Therefore, the proportion of disease-causing serotypes present in PCV7 is high in the United States, Canada and Australia (80-90%), followed by Europe and Africa (70-75%), Latin America (roughly 65%) and Asia (roughly 50%). 4 This proportion is low in Latin America due to the high prevalence of serotypes 1 and 5 in the region. [5] [6] [7] Thus arises a need for new vaccines that contain obtained from patients with pneumonia), 37.8% were penicillin-resistant. 11 In light of this growing resistance, penicillins are increasingly being rejected for both empirical and susceptibility-guided treatment, in favor of more expensive, broad-spectrum antibiotics. However, retrospective and prospective studies in adult and pediatric populations showed that the outcomes of pneumococcal pneumonias caused by purportedly resistant strains but treated with penicillin antibiotics did not differ from those obtained with other antimicrobial agents, suggesting that meningitis breakpoints did not apply to pneumonia. [12] [13] [14] Later multicenter studies confirmed these results. 15, 16 On the basis of these findings and of a review and S. pneumoniae strains were isolated from blood cultures using the BacT/ALERT ® detection system (Biomérieux, France), whereas pleural fluid specimens were cultured on chocolate agar and sheep blood agar (Biomérieux, Rio de Janeiro, Brazil). Pure cultures were taken from blood agar.
In this age range,
Organisms were identified at the HU-USP microbiology lab, 
Results
During the study period, the mean annual admission rate to the HU-USP pediatric ward was 1,535 patients. Of these, 720 per year (47%) were diagnosed with pneumonia.
S. pneumoniae was isolated from blood or pleural fluid cultures in approximately 2.5% of children hospitalized for pneumonia.
The final study sample comprised 107 children with a clinical and radiological diagnosis of pneumonia and growth of S. pneumoniae in blood and/or pleural fluid cultures.
In 75 cases (70%), pneumococci were isolated in blood cultures; in 16 (15%), from pleural fluid; and in 16 others (15%), from both.
Median age was 23 months; 51.4% of patients were aged ≤ 24 months and 82.2% were ≤ 5 years of age.
Associated conditions were present in 48 cases (44.9%):
wheezing in 37 (77.1%), chickenpox in 8 (16.7%), recurring pneumonia of undetermined etiology in 4 (8.3%), prematurity and/or bronchopulmonary dysplasia in 3 (6.3%), and heart disease in 3 (6.3%).
According to 2008 CLSI breakpoints, 100 isolates (93.5%) were penicillin-sensitive (MIC ≤ 2 µg/mL) and seven (6.5%) were penicillin-intermediate (MIC = 4 µg/mL).
No isolates were penicillin-resistant. The G-MIC of penicillin for serotype 14 increased progressively over the study period (Figure 2 ).
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Five pneumococcal strains were multidrug-resistant; in four, the MIC of penicillin was 4 µg/mL. Of these strains, of 528 pneumococcal strains isolated from pneumonia cases in Brazil, the most common serotypes were 14 (48.5%), 1 (13.4%), 6B (7.6%), 19A (4.4%) and 5 (4.2%). 11 In a study conducted in Salvador, Bahia, the serotypes isolated from 70 invasive strains of S. pneumoniae (77% isolated from children and adolescents with pneumonia) were 14 (22.9%), 5 and 6A (10% of cases each), 6B and 19F (8.6%
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Susceptibility of the S. pneumoniae strains isolated in our sample to non-penicillin antimicrobial agents is shown
in Table 1 .
All tested strains were sensitive to rifampicin and vancomycin. Several other agents showed high susceptibility rates, including chloramphenicol (99%), clindamycin (97.2%), ceftriaxone (94.6%), and levofloxacin (97.6%).
Erythromycin susceptibility was 97.2%. Of the three erythromycin-resistant strains isolated, two were crossresistant to clindamycin as well.
each), 9V, 18C and 23F (5.7% each). 19 A similar distribution was found in the present study.
Of the serotypes isolated in our study, 53. Penicillin resistance rates in 100 S. pneumoniae strains isolated from children aged 12 or younger with a diagnosis of pneumonia declined from 33 to 1% upon adoption of new CLSI breakpoints. 21 This wealth of data shows that penicillin antibiotics are still an excellent therapeutic option for treatment of pneumococcal pneumonia.
In the present study, seven S. pneumoniae strains were S. pneumoniae, Spain9V-3 and Tennessee. [14] [15] [16] [17] [18] The main reasons for abandoning penicillin in the treatment of pneumococcal pneumonia are the progressive increase of penicillin resistance in S. pneumoniae and the absence of a consensus on optimal dosage. 23 Pharmacokinetics and pharmacodynamics data suggest that, in the treatment of pneumonia, beta-lactam antibiotics are effective against pneumococci with MICs of up to 4 µg/mL. In children, therapeutic levels have been achieved at doses ranging from 100,000 to 300,000 IU/kg/day in 4 to 6 divided doses. 24, 25 For treatment of penicillin-intermediate strains (MIC = 4 µg/mL), which are still rare, adequate therapeutic levels can be achieved by doubling the daily dose of penicillin (200,000 IU/kg/day), even in the presence of complicated pleural effusions. 26 In the present study, G-MICs for penicillin were higher in isolates obtained from patients under the age of 2 years, probably due to greater antibiotic use and greater susceptibility to infection in this age range.
All pneumococcal strains isolated in the present study were highly sensitive to all antimicrobials except TMP-SMX, mirroring the findings of the SIREVA II project, 20 which found a resistance rate of 77.5% in isolates from patients aged ≤ 14 years.
Of the three erythromycin-resistant strains isolated, two Data from the present study, as did prior Brazilian studies, 5, 11, 19 show that the 10-valent pneumococcal conjugate vaccine, particularly due to its inclusion of serotypes 1 and 5, contains a greater proportion of invasive pneumonia-causing pneumococcal strains than the heptavalent vaccine. Likewise, when it becomes available, the 13-valent vaccine will contain a greater proportion of disease causing serotypes than its 10-valent counterpart.
According to current susceptibility criteria and the sensitivity findings reported herein, penicillin should still be considered the first-line drug of choice for treatment of invasive pneumococcal pneumonia.
